A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis

Rheumatology

Volumn 50, Issue 5, 2011, Pages 899-905

  Suppiah, Ravi ^a,b   Mukhtyar, Chetan ^c   Flossmann, Oliver ^d   Alberici, Federico ^e   Baslund, Bo ^f   Batra, Rajbir ^b   Brown, Denise ^b   Holle, Julia ^g   Hruskova, Zdenka ^h   Jayne, David R W ^c   Judge, Andrew ^b   Little, Mark A ⁱ   Palmisano, Alessandra ^e   Stegeman, Coen ^j   Tesar, Vladimir ^h   Vaglio, Augusto ^e   Westman, Kerstin ^k   Luqmani, Raashid ^a,b  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PARMA   (Italy)

^f Mental Health Center Glostrup   (Denmark)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ Centre for Nephrology   (United Kingdom)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^k Department of Endocrinology   (Sweden)

more..

Author keywords

Disease activity; Outcomes research; Systemic vasculitis; Vasculitis; Wegener's granulomatosis

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHURG STRAUSS SYNDROME; COHORT ANALYSIS; DISEASE ACTIVITY; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM; SYMPTOM; SYSTEMIC VASCULITIS; VALIDATION PROCESS; WEGENER GRANULOMATOSIS;

EID: 79955141104     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq400     Document Type: Article

References (26)

1. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40: 371-80.
2. Finkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-9.
3. Bertagna F, Bosio G, Caobelli F et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. Jpn J Radiol 2010;28: 199-204.
4. Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol 2009;21:19-28.
5. Zerizer I, Tan K, Khan S et al. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 2010;73:504-9.
6. Both M, Ahmadi-Simab K, Reuter M et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. Ann Rheum Dis 2008;67:1030-3.
7. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology 2008;47:403-8.
8. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
9. Luqmani RA, Exley AR, Kitas G et al. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-46.
10. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009;68:1827-32.
11. Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999;42:2365-71.
12. Flossmann O, Bacon P, de Groot K et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 2007;66:283-92.
13. Wegener's Granulomatosis Etanercept Trial Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
14. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
15. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
16. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
17. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8.
18. Jones R, Cohen Tevaert J, Hauser T et al. Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [Abstract]. APMIS 2009;117(Suppl. 127):78.
19. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
20. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002;41:572-81.
21. Exley AR, Carruthers DM, Luqmani RA et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 1997;90:391-9.
22. Hudson M, Steele R, Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93-8.
23. Lukas C, Landewe R, Sieper J et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68: 18-24.
24. van der Heijde D, Lie E, Kvien TK et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
25. Mahr AD, Neogi T, Lavalley MP et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum 2008;59:884-91.
26. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10.